Future options of anti-angiogenic cancer therapy by Yihai Cao
Cao  Chin J Cancer  (2016) 35:21 
DOI 10.1186/s40880-016-0084-4
REVIEW




In human patients, drugs that block tumor vessel growth are widely used to treat a variety of cancer types. Many 
rigorous phase 3 clinical trials have demonstrated significant survival benefits; however, the addition of an anti-angio-
genic component to conventional therapeutic modalities has generally produced modest survival benefits for cancer 
patients. Currently, it is unclear why these clinically available drugs targeting the same angiogenic pathways produce 
dissimilar effects in preclinical models and human patients. In this article, we discuss possible mechanisms of various 
anti-angiogenic drugs and the future development of optimized treatment regimens.
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Background
Treating cancer by blocking tumor angiogenesis, which 
was proposed by Judah Folkman nearly 45  years ago 
[1, 2], is now a universally accepted mechanism. Dec-
ades of experimental evidence have shown that solid 
tumor growth is dependent on angiogenic formation of 
new blood vessels [3]. Therefore, blocking tumor angio-
genesis could be a therapeutic option to treat all solid 
tumors. Indeed, in preclinical animal models, inhibition 
of tumor angiogenesis alone by agents that block angio-
genic factors and by generic inhibitors produces robust 
anti-tumor activities [4]. Some of these generic inhibi-
tors, such as angiostatin and endostatin, are present in 
humans (i.e., endogenous inhibitors, which may prevent 
the mature vasculature from further development [5–8]). 
Recent studies suggest that tumors can grow and invade 
through alternative mechanisms, including vascular 
mimicry and vascular co-option [9–14] (Fig. 1).
In preclinical tumor models, potent anti-cancer activ-
ity by angiogenesis inhibitors has been demonstrated; 
however, clinical studies with these inhibitors in human 
patients have shown different, and rather disappointing, 
data [15–17]. Targeting tumor blood vessels by angiogen-
esis inhibitors alone results in very few benefits for most 
cancer patients [15, 18–20]. Mechanistically, it is dif-
ficult to understand the differential responses of human 
cancer patients and mouse cancer models. Also, most 
clinically available anti-angiogenic drugs contain an anti-
vascular endothelial growth factor (VEGF) component as 
the primary target, and tumors may produce non-VEGF 
angiogenic factors to induce angiogenesis [21]. There-
fore, a small fraction of cancer patients may respond to 
anti-VEGF therapy, whereas other cancer patients might 
be intrinsically resistant to these drugs that do not spe-
cifically target the tumor angiogenic pathways. How do 
we discriminate responders from non-responders? Do we 
have many choices of drugs that target different angio-
genic pathways? Would these drugs be given to patients 
for the rest of their lives? Currently, these important 
issues remain unresolved.
Tumor size and patient survival
In almost all preclinical animal tumor models, the anti-
tumor effect of angiogenesis inhibitors is assessed by sup-
pression of tumor growth [4]. However, in clinical trials, 
survival improvement, especially improvement of overall 
survival, is the ultimate endpoint for clinical benefits. In 
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deciding whether to approve new anti-cancer drugs, the 
United States Food and Drug Administration (USA FDA) 
uses survival improvement, not tumor size reduction, as 
the determining criterion. Does tumor size associate with 
patient survival? It is probably true for some cancer patients.
However, tumor size is not a reliable predictor of sur-
vival of most cancer patients, and large tumors may not 
necessarily mean shortened lifespan [22]. Of the most 
common causes of cancer-related death, metastasis is 
probably responsible for most mortality [23]. It is known 
that cancer invasion and metastasis can occur at the 
early stage of primary tumor development [24, 25]. In 
fact, in a substantial number of cancer patients, the first 
sign of malignant disease is metastasis; primary tumors 
are often not detectable [26]. This means that dissemina-
tion of malignant cells from primary sites occurs at the 
early stage of cancer development, probably when the 
primary tumor is at microscopic size [24, 25]. In sup-
port of this, in a zebrafish model, investigators found that 
cancer cell intravasation into the circulation occurred 
when a primary tumor had only a few hundred cells [24, 
25]. In tumors, this small intravasation of tumor cells 
through the vessel wall occurs in surrounding pre-exist-
ing blood vessels, rather than in angiogenic vessels. Thus, 
when primary tumors lack an angiogenic phenotype, 
anti-angiogenic drugs would have only modest effects 
against cancer cell intravasation. Other primary causes 
of cancer-related death are cancer cachexia and other 
cancer-associated systemic diseases such as paraneoplas-
tic syndrome [27, 28]. Cancer cells and cancer-associated 
inflammation are able to trigger a catabolic pathway 
that causes severe adipose and muscular atrophy [29]. 
Although the mechanisms underlying malignant cells in 
manipulating the macro environment and the metabolic 
pathway in cancer hosts, several inflammatory cytokines, 
including interleukin-6 and tumor necrosis factor-α, have 
been shown, in preclinical tumor models, to induce can-
cer cachexia [30, 31]. For most cancer patients with most 
cancer types, cancer cachexia is directly associated with 
shortened survival and poor quality of life. For example, 
patients with pancreatic cancer often develop cachexia, 






























Fig. 1 Mechanisms of tumor blood supply in supporting tumor growth, metastasis, and drug resistance. Angiogenesis, vasculogenesis, and intus-
susception contribute to tumor neovascularization and tumor growth. Tumors may also use alternative mechanisms, including vascular mimicry, 
by which tumor cells but not endothelial cells form vessel-like structures. These tumor cell-constituted vessel-like structures can be perfused with 
blood to form blood lakes that support tumor growth. Alternatively, tumor cells can also adopt pre-existing vasculatures in their surrounding 
tissues—a process called co-option—for growth and metastasis. It has been suggested that both vascular mimicry and co-option contribute to the 
development of anti-angiogenic drug resistance
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Preclinical studies have commonly assessed the effect 
of any given anti-angiogenic agent on tumor growth for 
later clinical trials. Moreover, most studies aim to pre-
vent tumor growth by simultaneously delivering drugs 
and tumor cells to host animals [4]. Established tumors 
are rarely treated with anti-angiogenic agents. In clinical 
settings, anti-angiogenic therapy is initiated during the 
late stage of tumor development [20], which is probably 
less dependent on angiogenesis. This illustrates how the 
currently available preclinical models are not fully rel-
evant for human cancer patients. By better mimicking 
clinical situations, more reliable preclinical study results 
will be generated. Currently, such a clinically relevant 
model is still lacking. In clinical trials, most patients 
already have metastatic disease, and systemic delivery of 
anti-angiogenic drugs would inevitably affect metastatic 
tumor growth via blocking angiogenesis in metastatic 
nodules. This aspect is rarely considered in preclinical 
cancer models.
Biologics‑ and small compound‑based 
anti‑angiogenic drugs
Protein-based and chemical compound-based anti-
angiogenic drugs are currently available for treatment 
of human cancers [21]. Although these drugs commonly 
target the VEGF signaling pathway (Fig. 2), they exhibit 
different specificities. The antibody-based drugs, includ-
ing bevacizumab, aflibercept, and ramucirumab, are the 
most commonly used biologics, and they specifically bind 
to respective epitopes of the targeted molecules [33, 34]. 
Although these antibodies are monospecific with bind-
ing to their specific antigens, neutralization of a common 
target could potentially block functions of several angio-
genic factors (Fig. 3). For example, ramucirumab binds to 
vascular endothelial growth factor receptor 2 (VEGFR2) 
and blocks its interactions with VEGF-A, VEGF-C, and 
VEGF-D. Similarly, soluble VEGFR-based drugs such as 
aflibercept can neutralize several ligands as one receptor 
binds to several ligands, including VEGF-A, VEGF-B, and 
placental growth factor [35]. Conversely, bevacizumab is 
a monospecific drug that blocks only VEGF-A without 
affecting other signaling pathways.
In contrast to antibody-based and soluble receptor-
based biologics, small chemical compound-based drugs 
are far less specific. The most commonly used tyrosine 
kinase inhibitors (TKIs) that block VEGFR-mediated 
signaling pathways are small chemical molecules target-
ing a broad spectrum of kinases [36, 37]. Most VEGFR-
TKIs, including sunitinib, sorafenib, and pazopanib, 
indistinguishably target VEGFR1, VEGFR2, and VEGFR3 
signaling pathways. Additionally, these receptor inhibi-
tors also block many other receptor kinases that are 
not parts of the VEGFR family but are often related to 
angiogenic signaling pathways, including members of 
the platelet-derived growth factor (PDGF) receptor and 
fibroblast growth factor (FGF) receptor families [38].
Theoretically, anti-angiogenic drugs that target abroad 
spectrum of signaling pathways would be more desirable 
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Fig. 2 Anti-angiogenic drug targets. Monospecific bevacizumab, 2–3-targeted aflibercept and ramucirumab, and multi-targeted tyrosine kinase 
inhibitor anti-angiogenic drugs are currently used to treat cancer in human patients
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and effective for treating cancer since malignant tissues 
are heterogeneous with different populations of tumor 
and host cells that produce various angiogenic factors. In 
this regard, anti-angiogenic TKIs would be more effective 
than antibody-based and soluble receptor-based drugs 
that solely target the VEGF pathway. However, clinical 
experience with anti-angiogenic therapy shows that TKIs 
may not necessarily be more effective than bevacizumab. 
Additionally, anti-angiogenic TKIs and bevacizumab 
show different profiles of toxicity, although both classes 
of drugs commonly cause some adverse effects. An 
important difference between biologics and TKIs is that 
antibody-based drugs have a longer half-life than small 
chemical molecules. They are inactivated using different 
metabolic pathways.
Anti‑angiogenic drug targets
Anti-angiogenic drugs target tumor blood vessels that 
exhibit heterogeneity [39]. However, none of available 
drugs are specifically delivered to the tumor tissue. They 
are delivered systemically to cancer patients, exposing all 
the tissues and organs to the drugs [22]. Would systemic 
delivery of anti-angiogenic drugs affect non-tumoral 
healthy vasculatures? In tumor-free healthy mice, sys-
temic treatment with anti-angiogenic drugs, including 
an anti-VEGF neutralizing antibody and TKI-targeting 
VEGFRs, resulted in robust vascular regression in many 
tissues and organs. In all tissues, vasculatures in endo-
crine organs, including the thyroid, adrenal gland, ovary, 
and pancreatic β-islets, underwent robust regression in 
response to systemic anti-angiogenic therapy [40]. For 
example, after receiving only a 2-week treatment with a 
mouse version of bevacizumab, the mice lost more than 
70% of pre-existing microvessels to the thyroid [41]. In 
addition to changes in vascular density, the endothelia 
underwent structural changes by replacing fenestrae with 
the intracellular vesiculo-vacuolar organelles. In normal 
physiological conditions, VEGF is a crucial hemostatic 
factor for endothelial cell survival and endothelium fen-
estrations in endocrine vasculatures. Thus, systemic 
inhibition of VEGF function would inevitably cause 
structural changes and decreases in vascular density. The 
anti-angiogenic drug-induced vascular changes also pro-
duce functional alterations in their respective organs. For 
example, thyroid hormones are significantly decreased 
after prolonged treatment with anti-VEGF drugs, result-
ing in hypothyroidism [41].
In addition to causing changes to the endocrine organs, 
anti-VEGF drugs also induce rigorous vascular regression 
in the liver, gastrointestinal wall, and kidney cortex [41]. 
Vascular regression inevitably creates a hypoxic environ-
ment in the targeted tissues and organs that eventually 
affects organ functions. These functional changes mani-
fest as clinically adverse effects, such as hypertension, 
gastrointestinal perforation, hemorrhages, and protein 
in urine, which are commonly seen in cancer patients 
who are treated with anti-angiogenic drugs [15, 38, 42]. 
Paradoxically, off-tumor targets of anti-VEGF drugs can 
sometimes be beneficial for cancer patients [22]. This is 
particularly the case if circulating VEGF expression levels 
are extremely high in the patients whose tumors produce 
high amounts of VEGF. For example, in patients with von 
Hippel–Lindau (Vhl) gene-mutated renal cell carcinoma, 
VEGF expression levels can be very high [43]. Circulating 
VEGF also causes destructive effects in remote healthy 
tissues and organs, such as the bone marrow, liver, and 
spleen [44]. In this case, inhibition of VEGF-induced vas-
cular impairment would potentially improve patient sur-
vival, as shown in preclinical models.
Therapeutic timeline
An important and clinically practical issue related to 
anti-angiogenic therapy is length of treatment. How long 
should a cancer patient be treated with anti-angiogenic 
drugs? What would happen if anti-angiogenic treatment 
was discontinued? Currently, no consensus exists regard-
ing treatment timeline with anti-angiogenic drugs. As 
an anti-angiogenic component is added to the standard 
chemotherapy regimen, anti-angiogenic therapy follows 
the timeline of chemotherapy. In clinical practice, anti-
angiogenic treatment will inevitably be discontinued. 








Fig. 3 VEGF signaling and anti-VEGF drug targets. VEGF stimulates 
tumor angiogenesis by activating endothelial VEGFR2 and its down-
stream signaling. Drugs targeting various signaling components have 
been developed for clinical use. VEGF vascular endothelial growth 
factor, VEGFR2 vascular endothelial growth factor receptor 2
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in adverse effects that make therapy withdrawal difficult. 
Similarly, if patients acquire drug resistance during treat-
ment, this can also result in discontinuation of therapy. 
[A non-scientific reason for discontinuation of treatment 
is the economic burden incurred by patients (Fig. 4)]. In 
animal cancer models, discontinuation of anti-angiogenic 
therapy resulted in rapid regrowth of tumor blood ves-
sels [45]. For small chemical compound-based drugs, 
revascularization occurs 2–3 days after drug withdrawal 
and reaches a maximal level around day 7. Around this 
time, revascularization generates a rebound time window 
that drives angiogenesis to a level higher than it was prior 
to treatment [41]. It is possible that rebound angiogen-
esis reflects the time course of angiogenic vessel growth 
before vascular remodeling and maturation.
It is unclear if, after discontinuation of anti-angiogenic 
therapy, rebound angiogenesis also occurs in human 
patients. However, reasonable speculation suggests that 
human tumors and mouse tumors would respond simi-
larly. If rebound angiogenesis does occur in human can-
cer patients, discontinuation of anti-angiogenic therapy 
could potentially result in accelerated tumor growth. 
Thus, non-stop, lifetime anti-angiogenic treatment 
should be recommended. In support of this view, pro-
longed anti-angiogenic therapy has resulted in prolonged 
survival for human cancer patients.
Drug resistance
Originally, researchers believed that angiogenesis inhibi-
tors, especially the endogenous inhibitors such as angio-
statin, endostatin, and other generic inhibitors, would not 
develop drug resistance of tumor cells because they target 
endothelial cells rather than tumor cells [46, 47]. Unlike 
malignant cells, endothelial cells, even those located in 
tumor tissues, have stable genomes and do not seem to 
use the canonical drug-resistant mechanisms. However, 
both experimental and clinical findings have challenged 
this view. Some studies showed that endothelial cells in 
angiogenic tumor vessels contain aberrant genomes that 
would not be present in healthy vasculatures [48]. It is 
unclear if the tumor-like aberrant genetic information 
in endothelial cells is transferred from tumor cells or if 
the intrinsic development genomic instability develops in 
endothelial cells. Inhibition of tumor angiogenesis could 
alter the cellular and molecular components in the tumor 
microenvironment, leading to development of drug 
resistance. For example, anti-angiogenic drug–induced 
vascular regression in the tumors creates tissue hypoxia 
in a local microenvironment, which augments expression 
levels of multiple angiogenic factors unrelated to the drug 
targets [36, 49]. Investigators have shown that anti-VEGF 
drugs develop resistance of tumor cells by this compensa-
tory mechanism. Moreover, anti-VEGF drugs also tip the 
balance between various cellular compositions, includ-
ing inflammatory cells and stromal fibroblasts, which are 
important sources of cytokines and non-VEGF angio-
genic factors that contribute to drug resistance [50, 51].
Alternative mechanisms of tumor neovascularization 
that are not affected by drug targets also contribute to 
anti-angiogenic drug resistance. For example, vessel co-
option, vascular mimicry, intussusception, and vascu-
logenesis support tumor growth and potentially inhibit 
anti-angiogenic treatment [10, 37, 52–54]. In patients 
who demonstrate intrinsic resistance to anti-VEGF 
therapy, non-VEGF angiogenic factors probably stimu-
late angiogenesis in their tumors. Thus, combination 
therapeutic approaches that target different angiogenesis 
signaling pathways would likely be more effective. Also, 
patients who take multi-targeted drugs such as TKIs 
would be less likely to develop drug resistance. Impor-
tantly, cross-communication between different angio-
genic signaling pathways can generate synergistic effects, 
even though expression levels of each individual fac-
tor are low. For example, the synergistic effects between 
FGF receptor 2 and PDGF-BB on angiogenesis promote 
tumor growth and metastasis [55, 56].
Mechanisms of combination therapy
In clinical practice, combination therapy represents a 
major mechanistic challenge [57]. Why would clini-
cal benefits be achieved by combining anti-angiogenic 
drugs with chemotherapy? Why would anti-angiogenic 
treatment alone be sufficiently effective? A few possible 
hypotheses may explain the mechanism underlying com-
bination therapy. One hypothesis suggests that treatment 
with anti-angiogenic drugs produces a normalized vascu-
lar phenotype, which increases vascular perfusion rather 
than decreases it [58]. In the presence of chemothera-
peutic agents, increased vascular perfusion enables more 
cytotoxic drugs to reach the tumors, leading to increased 




Fig. 4 Effects of ON and OFF treatment with anti-angiogenic drugs 
on tumor vasculatures. Rapid revascularization and rebound angio-
genesis can occur after treatment is discontinued
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tumor cell death. In other words, when administered with 
chemotherapeutics, anti-angiogenic treatment inhibits 
tumor growth. Also, the results of animal tumor models 
have demonstrated that anti-angiogenic drug-induced 
vascular normalization occurs within a limited time 
during treatment (i.e., the “vascular normalization win-
dow”) [59]. The mechanism underlying how combination 
therapy relates to vascular normalization is a paradox. If 
anti-angiogenic drugs induce vascular normalization and 
possibly blood perfusion in tumors, tumor growth would 
be accelerated. However, in both preclinical cancer mod-
els and clinical cancer patients, anti-angiogenic treat-
ment does not promote tumor growth, although some 
researchers have suggested that the treatment facilitates 
cancer invasion [60, 61].
Another experimental study suggested that the mecha-
nism underlying combination therapy can be explained 
by a decrease of chemotherapeutic toxicity [62]. Chem-
otherapeutics produce a broad spectrum of toxicity, 
including suppression of bone marrow hematopoiesis 
and high levels of circulating VEGF. Many cancer 
patients have high levels of circulating VEGF and mani-
fest anemia [63]. A causal relationship between VEGF 
and anemia in human cancer patients has yet to be estab-
lished, but studies of animal cancer models have shown 
that tumor-derived high-circulating VEGF causes severe 
anemia [44]. In high VEGF-producing tumor-bearing 
mice, chemotherapy and VEGF synergistically sup-
pressed bone marrow hematopoiesis, resulting in early 
death [62]. Anti-VEGF treatment ablates VEGF-induced 
anemia and thus increases tolerance of chemotoxicity. 
Sequential delivery of anti-angiogenic therapy prior to 
the initiation of chemotherapy prolongs patient’s survival 
[62]. Anti-angiogenic drugs recover bone marrow hemat-
opoiesis prior to chemotherapy and increase tolerance of 
chemotoxicity [62]. If this regimen were approved for at 
least a subset of human cancer patients, it would prob-
ably result in substantially increased survival benefits for 
these patients.
Predictive biomarker‑related issues
Mono-specific anti-VEGF drugs such as bevacizumab 
target only VEGF without binding to other proteins. 
VEGF expression levels would serve as a reliable predic-
tive marker for selecting cancer patients who are likely 
to benefit from anti-VEGF therapy. Based on more than 
10 years of clinical experience with various cancer types, 
simply measuring VEGF expression levels, in either the 
circulation or tumor biopsies, has not fulfilled the cri-
terion for predicting responders [64–68]. Why would 
VEGF, as the sole target for bevacizumab, not serve as 
a reliable predictive marker for patient selection? There 
is no satisfactory answer to this puzzling question. 
However, some researchers have suggested that measur-
ing different isoforms of VEGF might more reliably pre-
dict responders of anti-VEGF therapy [69–71]. Smaller 
VEGF isoforms, including VEGF121, lack heparin-bind-
ing affinity and diffuse distally from their productive 
sites. Additionally, proteolytically processed smaller ver-
sions of VEGF can also lack high heparin-binding affin-
ity and can be transported to distal tissues and organs. 
Interestingly, these small versions of VEGF proteins have 
some predictive values, although their targets may not be 
limited to tumor tissues. It is possible that off-tumor tar-
gets of these small VEGF proteins predict their therapeu-
tic values [22]. Indeed, based on preclinical and clinical 
findings, the potentially beneficial effects of anti-VEGF 
drug off-tumor targets have been proposed [22].
Many physiological, cellular, and molecular biomarker 
candidates related to anti-angiogenic therapy-induced 
adverse effects have been proposed, but in clinical prac-
tice physiological responses are the most commonly 
used biomarkers. For example, anti-angiogenic drug-
induced hypertension has been associated with clinical 
benefits; however, the molecular mechanism underlying 
the benefit is unknown [72–78]. Given that adding anti-
angiogenic components to conventional chemotherapy 
is widely used for the treatment of cancer, significant 
clinical benefits without selection biomarkers are truly 
valuable. Assuming a reliable predictive biomarker exists, 
treating a selected population of responders with anti-
angiogenic drugs would likely markedly increase clinical 
benefits. Future efforts should focus on identifying such a 
reliable biomarker for clinical use.
Adverse effects
Systemic delivery of anti-angiogenic drugs to can-
cer patients would inevitably expose non-cancerous 
healthy tissues to these drugs [40, 41]. In preclinical 
studies, investigators have shown that systemic treat-
ment induces vascular changes in multiple tissues and 
organs. For example, in mice, systemic anti-angiogenic 
therapy caused marked regression of approximately 70% 
of microvessels in the thyroid and, to a lesser extent, in 
other endocrine organs, such as the adrenal gland and 
pancreatic islets [40, 41]. Additionally, anti-VEGF ther-
apy caused a marked reduction in micro vasculatures in 
the liver, kidney, and gastrointestinal wall [40, 41]. Vas-
cular changes in non-tumor tissues are associated with 
clinical adverse effects, including hypertension, hypothy-
roidism, gastrointestinal perforation, and cardiovascular 
disease [15, 79]. Since VEGF is an important hemostatic 
factor for maintaining the number and structure of 
microvessels in various tissues and organs, it is perhaps 
not surprising that anti-VEGF-based anti-angiogenic 
drugs would cause broad adverse effects.
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How would anti-angiogenic drugs be directly deliv-
ered to tumorous tissues without affecting the healthy 
vasculature? Designing a new generation of targeted 
drugs would be a very challenging task. Even though 
anti-angiogenic drugs are locally injected into tumor-
ous tissues, they still enter the circulation. Additionally, 
this approach would prevent anti-angiogenic agents from 
reaching metastatic tumors. In fact, clinical indications 
of using anti-angiogenic therapies approved by the U.S. 
FDA often include metastatic disease.
Perspectives
Inhibition of angiogenesis for the treatment of cancer 
has been successfully translated into clinical use. The key 
issue is that patients who receive anti-angiogenic drugs 
experience relatively few clinical benefits. For patients 
with some cancer types, including pancreatic cancer and 
breast cancer, the addition of an anti-angiogenic com-
ponent to chemotherapy has not produced meaningful 
improvement in overall survival. If all solid tumor growth 
depends on angiogenesis, why would anti-angiogenic 
treatments not be beneficial? Why would anti-angiogenic 
monotherapies fail to demonstrate clinical benefits? 
What is the mechanistic rationale of combination ther-
apy with chemotherapeutics? Could a predictive marker 
be identified? How long should cancer patients be treated 
with anti-angiogenic drugs? What could happen if the 
anti-angiogenic therapy is discontinued? Would combi-
nations of drugs that target different angiogenic pathways 
improve therapeutic outcomes? There are no unified 
opinions on these clinical issues. Possibly, an important 
means to address these issues is to establish clinically rel-
evant cancer models in animals. Given sophisticated can-
cer biology, metastatic disease, and systemic disorders 
in cancer patients, the complex mechanisms underlying 
malignant disease cannot likely be simply explained. The 
same type of cancer in different patients may represent a 
different disease. Likewise, the same cancer in the same 
patient may represent a different disease at different 
stages of progression. This means that personalized med-
icine may not be sufficiently effective and that dynamic 
approaches should be developed for treating cancer at 
different stages during disease development. In clini-
cal practice, developing both personalized therapy and 
dynamic therapy is an extremely challenging task.
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